About ArpIda
ArpIda is a company based in Reinach (Switzerland) founded in 1997 was acquired by Evolva in September 2009. ArpIda has raised $90.4 million across 3 funding rounds from investors including Evolva, Carlsberg Group and O-Bank. ArpIda operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Reinach, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ArpIda
ArpIda has successfully raised a total of $90.4M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $26.4 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ArpIda
ArpIda has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Evolva, Carlsberg Group and O-Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for ArpIda
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArpIda
Investment portfolio details for ArpIda
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ArpIda
Detailed financials for ArpIda
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arpida Comparisons
Peer comparison for ArpIda
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ArpIda
ArpIda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of ArpIda
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arpida
Complete news archive for ArpIda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArpIda
ArpIda was founded in 1997 and raised its 1st funding round 3 years after it was founded.
ArpIda is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
ArpIda is a funded company, having raised a total of $90.4M across 3 funding rounds to date.
ArpIda was founded in 1997 and is based in Reinach, Switzerland. Operations center on the pharmaceutical sector, with emphasis placed on antibiotics to address microbial resistance. The lead product candidate, intravenous iclaprim, is designed for hospital-treated severe infections, such as those from methicillin-resistant Staphylococcus aureus (MRSA). Development efforts target unmet needs in infectious disease management.
ArpIda's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
ArpIda has 8 investors. Key investors include Evolva, Carlsberg Group, O-Bank, CDIB Capital Group, and LD Fonde.